demethyloxyphenonium | 3570-96-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: demethyloxyphenonium
• 英文别名: cyclohexyl-hydroxy-phenyl-acetic acid-(2-diethylamino-ethyl ester)；Cyclohexyl-hydroxy-phenyl-essigsaeure-(2-diaethylamino-aethylester)；(+/-)-Cyclohexyl-phenyl-glykolsaeure-<2-diaethylamino-aethylester>；Cyclohexyl-phenyl-glykolsaeure-<2-diaethylamino-aethylester>；Cyclohexyl-phenyl-glykolsaeure-(2-diaethylamino-aethylester)；2-(Diethylamino)ethyl cyclohexyl(hydroxy)phenylacetate；2-(diethylamino)ethyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
• CAS: 3570-96-5；123067-11-8；123067-12-9
• 化学式: C₂₀H₃₁NO₃
• 分子量: 333.471
• InChiKey: YXUBHIRQBSIPFE-UHFFFAOYSA-N

物化性质

• 沸点：
  458.2±30.0 °C(Predicted)
• 密度：
  1.077±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.1
• 重原子数：
  24
• 可旋转键数：
  9
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  49.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  demethyloxyphenonium 生成 diethyl-{2-[(cyclohexyl-hydroxy-phenyl)-acetoxy]-ethyl}-methyl-ammonium; iodide
  参考文献：
  名称：

  关于碱性酯III的表示

  摘要：

  DOI：

  10.1002/hlca.19470300136
• 作为产物：
  描述：

  环己基溴化镁 在 potassium carbonate 、 乙酸乙酯 作用下， 生成 demethyloxyphenonium
  参考文献：
  名称：

  关于碱性酯III的表示

  摘要：

  DOI：

  10.1002/hlca.19470300136

文献信息

• Compositions and Methods for Transdermal Oxybutynin Therapy
  申请人：Ebert Charles D.

  公开号：US20090018190A1

  公开（公告）日：2009-01-15

  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

  本发明提供了组合物和方法，用于在最小化与氧丁宁治疗相关的不良药物反应的发生率和/或严重程度的同时给予氧丁宁。在一个方面，这些组合物和方法提供了较低的氧丁宁代谢物，如N-去乙氧基氧丁宁的血浆浓度，这被认为至少在某种程度上有助于某些不良药物反应的发生，同时保持足够的氧丁宁血浆浓度，以使受试者从氧丁宁治疗中受益。本发明还提供了满足这些最小化不良药物反应发生率和/或严重程度特征的氧丁宁及其代谢物的异构体，并维持膀胱过度活动的有益和有效治疗。在某些方面，该组合物可以以未遮盖或自由形式局部给药凝胶的形式呈现。
• Compositions and methods for transdermal oxybutynin therapy
  申请人：Ebert D. Charles

  公开号：US20070148195A1

  公开（公告）日：2007-06-28

  The present invention provides compositions and methods for administering oxybutynin while minimizing the incidence and or severity of adverse drug experiences associated with oxybutynin therapy. In one aspect, these compositions and methods provide a lower plasma concentration of oxybutynin metabolites, such as N-desethyloxybutynin, which is presumed to be contributing at least in part to some of the adverse drug experiences, while maintaining sufficient oxybutynin plasma concentration to benefit a subject with oxybutynin therapy. The invention also provides isomers of oxybutynin and its metabolites that meet these characteristics of minimized incidence and/or severity of adverse drug experiences, and maintenance of beneficial and effective therapy for overactive bladder. In some aspects, the composition may be presented in the form of an unoccluded or free form topically administered gel.

  本发明提供了组合物和方法，用于在最小化与氧丁宁治疗相关的不良药物反应的发生率和/或严重程度的同时给予氧丁宁。在其中一个方面，这些组合物和方法提供了较低的氧丁宁代谢物，例如N-去乙氧基氧丁宁的血浆浓度，这被认为至少部分地促成了某些不良药物反应，同时保持足够的氧丁宁血浆浓度以使受试者从氧丁宁治疗中受益。本发明还提供了满足这些最小化不良药物反应的发生率和/或严重程度以及维持膀胱过度活动的有益和有效治疗的氧丁宁及其代谢物的异构体。在某些方面，该组合物可以以未封闭或自由形式的局部给药凝胶的形式呈现。
• CRYSTALLINE OXYBUTYNIN AND PROCESS FOR PREPARING THE SAME
  申请人：Ray Chandra Purna

  公开号：US20110087042A1

  公开（公告）日：2011-04-14

  The present invention relates to a crystalline oxybutynin base and process for preparing the same. Further, this invention discloses a process for preparing an acid addition salt of oxybutynin employing the crystalline oxybutynin base.

  本发明涉及一种结晶的氧丁宁碱和制备方法。此外，本发明还公开了一种使用该结晶的氧丁宁碱制备酸加成盐的方法。
• DE739151
  申请人：——

  公开号：——

  公开（公告）日：——
• CARBAMATES DERIVED FROM ARYLALKYLAMINES
  申请人：LABORATORIOS S.A.L.V.A.T., S.A.

  公开号：EP1300407B2

  公开（公告）日：2011-06-08